Treatment of hepatitis B virus-related polyarteritis nodosa: two case reports and a review of the literature

• Published in: Clinical rheumatology 2004-04, Vol.23 (2), p.172-176
• Main Authors: Deeren, D H, De Backer, A I, Malbrain, M L N G, Verbraeken, H, Blockmans, D
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - therapeutic use; Antiviral Agents - therapeutic use; Combined Modality Therapy; Drug Therapy, Combination; Fatal Outcome; Glucocorticoids - therapeutic use; Hepatitis; Hepatitis B - complications; Hepatitis B - therapy; Hepatitis B virus - isolation & purification; Humans; Lamivudine - therapeutic use; Magnetic Resonance Imaging; Male; Middle Aged; Plasma Exchange; Polyarteritis Nodosa - therapy; Polyarteritis Nodosa - virology; Tomography, X-Ray Computed; Treatment Refusal
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-003-0857-4

A substantial number of cases of polyarteritis nodosa (PAN) are related to hepatitis B virus (HBV) infection. Different treatment strategies are reported in the literature. The aim of this study was to review 15 years of literature (1988-2002) to determine the optimal treatment for HBV-related PAN at present, and to discuss the indications and mechanism of action of corticosteroids in HBV-related PAN, as many physicians are reluctant to use these in the presence of HBV infection. The first patient stopped his initial treatment, relapsed and died of cerebral infarction. The second case illustrates the favorable outcome with the standard treatment: corticosteroids, lamivudine and plasma exchanges. If adequate follow-up is possible, antiviral agents as well as corticosteroids are indicated in HBV-related PAN. Corticosteroids diminish inflammation and corticosteroid withdrawal induces an alanine aminotransferase (ALT) rebound in patients with a low baseline ALT level. Antiviral agents are essential, as they reduce the production of HBV antigens and help to achieve hepatitis B early antigen (HBeAg) seroconversion. Plasma exchanges reduce the level of circulating immune complexes and are included in the treatment protocol of all recent studies. However, their effect has not been evaluated in controlled trials. We concluded that if adequate follow-up is possible, antiviral agents as well as corticosteroids are indicated in HBV-related PAN.